论文部分内容阅读
目的分析川芎嗪对慢性肾衰竭患者肾功能的影响。方法随机双盲法将符合纳入标准的80例慢性肾衰竭患者分为2组各40例,对照组采取常规治疗,观察组在对照组基础上加以川芎嗪注射液治疗,比较两组患者治疗前后血尿素氮(blood urea nitrogen,BUN)、血肌酐(serum creatinine,Scr)、尿微量白蛋白、24 h尿蛋白、纤维蛋白原(fibrinogen,FIB)、D-二聚体(D-dimer,D-D)水平变化及不良反应情况。计量资料比较采用t检验,P<0.05为差异有统计学意义。结果观察组治疗后BUN、Scr、尿微量白蛋白及24 h尿蛋白[(14.0±5.1)mmol/L、(180.2±75.4)μmol/L、(153.2±69.5)mg/L、(2.7±0.7)g/L]均较治疗前[(19.2±5.9)mmol/L、(258.4±78.6)μmol/L、(189.6±77.8)mg/L、(3.3±0.8)g/L]明显下降,比较差异有统计学意义(t=4.22、4.54、2.21、3.57,均P<0.05);对照组治疗后BUN、Scr[(16.4±5.5)mmol/L、(214.7±70.6)μmol/L]均明显降低,较治疗前比较差异均有统计学意义(t=2.00、2.73,均P<0.05);两组治疗后BUN、Scr比较,差异有统计学意义(t=2.02、2.11,均P<0.05)。观察组治疗后FIB及D-D[(3.30±1.65)g/L、(0.88±0.81)mg/L]均明显下降,较治疗前[(4.15±1.67)g/L、(1.41±0.86)mg/L]比较,差异有统计学意义(t=2.29、2.84,均P<0.05);观察组治疗后FIB及D-D水平均明显低于对照组,差异均有统计学意义(t=2.04、2.03,均P<0.05)。结论川芎嗪注射液能明显改善患者的肾功能,显著降低血浆FIB及D-D水平,且安全性高。
Objective To analyze the effect of ligustrazine on renal function in patients with chronic renal failure. Methods A total of 80 patients with chronic renal failure who met the inclusion criteria were randomly divided into two groups (n = 40). The control group was treated with conventional therapy. The observation group was treated with ligustrazine on the basis of the control group. Before and after treatment Blood urea nitrogen (BUN), serum creatinine (Scr), urinary microalbumin, 24 h urinary protein, fibrinogen (FIB) and D-dimer ) Level changes and adverse reactions. Measurement data were compared using t test, P <0.05 for the difference was statistically significant. Results After treatment, the levels of BUN, Scr, urinary albumin and 24 h urinary protein in the observation group [(14.0 ± 5.1) mmol / L, (180.2 ± 75.4) μmol / L, (153.2 ± 69.5) mg / ) were significantly lower than those before treatment [(19.2 ± 5.9) mmol / L, (258.4 ± 78.6) μmol / L, (189.6 ± 77.8) mg / L, (3.3 ± 0.8) g / L] The difference was statistically significant (t = 4.22,4.54,2.21,3.57, all P <0.05); the BUN, Scr [(16.4 ± 5.5) mmol / L, (214.7 ± 70.6) μmol / L] (T = 2.00, 2.73, all P <0.05). There was significant difference between the two groups after treatment (t = 2.02,2.11, all P <0.05) ). The FIB and DD [(3.30 ± 1.65) g / L, (0.88 ± 0.81) mg / L] in the observation group were significantly lower than those before treatment [(4.15 ± 1.67) g / (T = 2.29,2.84, all P <0.05). The levels of FIB and DD in the observation group were significantly lower than those in the control group (t = 2.04, 2.03, All P <0.05). Conclusion Ligustrazine injection can significantly improve renal function, significantly reduce the plasma FIB and D-D levels, and high safety.